Skip to content

Study · Randomized controlled trial · n = 426 · 2023

9 results

iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.

Guo X, Yang W, Zhang J, Dong X, Liu M, Gu S, Lauand F, Li L, Huang Q, Kang L, Souhami E

Diabetes, obesity & metabolism3 May 2023Cited by 7 (Europe PMC)

PMID36999231 (opens in a new tab)DOI10.1111/dom.15074 (opens in a new tab)PepBankPUB-36999231
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In insulin-treated Asian Pacific people with diabetes, iGlarLixi increased dTIR more than glargine (ETD 16.59%, 95% CI 12.09% to 21.08%).

    In plain wordsIn insulin-treated Asian Pacific people with diabetes, adding lixisenatide increased time in glucose range more than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDerived time-in-range change, LixiLan-L-CN
    Study

    n = 426

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Estimated treatment difference in dTIR change versus iGlar
    16.59%
    iGlarLixi vs iGlar, LixiLan-L-CN; 95% CI 12.09% to 21.08%

    Source sentences

    Summary
    The changes from baseline to EOT in dTIR with iGlarLixi were greater versus iGlar (ETD1 : 11.45% [95% CI, 7.66% to 15.24%]) or Lixi (ETD2 : 20.54% [95% CI, 15.74% to 25.33%]) in LixiLan-O-AP, and versus iGlar (ETD: 16.59% [95% CI, 12.09% to 21.08%]) in LixiLan-L-CN.
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In LixiLan-L-CN, 71.4% receiving iGlarLixi versus 45.4% receiving glargine achieved at least 70% dTIR at treatment end.

    In plain wordsIn insulin-treated Asian Pacific people with diabetes, more participants reached the glucose-range target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAt least 70% dTIR response, LixiLan-L-CN
    Study

    n = 426

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR 70% or higher at end of treatment
    71.4%
    iGlarLixi, LixiLan-L-CN
    Patients with dTIR 70% or higher at end of treatment
    45.4%
    iGlar, LixiLan-L-CN

    Source sentences

    Summary
    In LixiLan-L-CN, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT were 71.4% and 59.8% with iGlarLixi, greater than with iGlar (45.4% and 39.5%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In LixiLan-L-CN, 59.8% receiving iGlarLixi versus 39.5% receiving glargine achieved at least 5% dTIR improvement at treatment end.

    In plain wordsIn insulin-treated Asian Pacific people with diabetes, more participants improved time in glucose range with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAt least 5% dTIR improvement, LixiLan-L-CN
    Study

    n = 426

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR improvement of 5% or higher at end of treatment
    59.8%
    iGlarLixi, LixiLan-L-CN
    Patients with dTIR improvement of 5% or higher at end of treatment
    39.5%
    iGlar, LixiLan-L-CN

    Source sentences

    Summary
    In LixiLan-L-CN, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT were 71.4% and 59.8% with iGlarLixi, greater than with iGlar (45.4% and 39.5%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In insulin-naive Asian Pacific people with diabetes, iGlarLixi increased dTIR more than glargine (ETD 11.45%, 95% CI 7.66% to 15.24%).

    In plain wordsIn insulin-naive Asian Pacific people with diabetes, adding lixisenatide increased time in glucose range more than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDerived time-in-range change, LixiLan-O-AP
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Estimated treatment difference in dTIR change versus iGlar
    11.45%
    iGlarLixi vs iGlar, LixiLan-O-AP; 95% CI 7.66% to 15.24%

    Source sentences

    Summary
    The changes from baseline to EOT in dTIR with iGlarLixi were greater versus iGlar (ETD1 : 11.45% [95% CI, 7.66% to 15.24%]) or Lixi (ETD2 : 20.54% [95% CI, 15.74% to 25.33%]) in LixiLan-O-AP, and versus iGlar (ETD: 16.59% [95% CI, 12.09% to 21.08%]) in LixiLan-L-CN.
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In LixiLan-O-AP, 77.5% receiving iGlarLixi versus 61.1% receiving glargine achieved at least 70% dTIR at treatment end.

    In plain wordsIn insulin-naive Asian Pacific people with diabetes, more participants reached the glucose-range target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAt least 70% dTIR response, LixiLan-O-AP
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR 70% or higher at end of treatment
    77.5%
    iGlarLixi, LixiLan-O-AP
    Patients with dTIR 70% or higher at end of treatment
    61.1%
    iGlar, LixiLan-O-AP

    Source sentences

    Summary
    In LixiLan-O-AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In LixiLan-O-AP, 77.8% receiving iGlarLixi versus 75.3% receiving glargine achieved at least 5% dTIR improvement at treatment end.

    In plain wordsIn insulin-naive Asian Pacific people with diabetes, more participants improved time in glucose range with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseAt least 5% dTIR improvement, LixiLan-O-AP
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR improvement of 5% or higher at end of treatment
    77.8%
    iGlarLixi, LixiLan-O-AP
    Patients with dTIR improvement of 5% or higher at end of treatment
    75.3%
    iGlar, LixiLan-O-AP

    Source sentences

    Summary
    In LixiLan-O-AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In Asian Pacific people with diabetes, more participants achieved the triple glucose-range target with iGlarLixi than glargine.

    In plain wordsIn Asian Pacific people with diabetes, more participants reached the triple glucose-range target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseComposite triple target response
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    More patients achieved the triple target with iGlarLixi compared with iGlar or Lixi.
    3 context sentences
    Summary · context
    The proportions of patients achieving 70% or higher derived time-in-range (dTIR), 5% or higher dTIR improvement, and the composite triple target (≥ 70% dTIR, < 4% derived time-below-the-range [dTBR] and < 25% derived time-above-the-range [dTAR]) were calculated.
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  8. 08HumanNon-randomized trialEfficacy outcome

    In LixiLan-O-AP, 47.0% receiving lixisenatide alone achieved at least 70% dTIR at treatment end.

    In plain wordsIn insulin-naive Asian Pacific people with diabetes, 47.0% receiving lixisenatide alone reached the glucose-range target.

    Peptide
    Lixisenatide
    Outcome
    Not applicableAt least 70% dTIR response with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR 70% or higher at end of treatment
    47%
    Lixi alone, LixiLan-O-AP

    Source sentences

    Summary
    In LixiLan-O-AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.
  9. 09HumanNon-randomized trialEfficacy outcome

    In LixiLan-O-AP, 53.0% receiving lixisenatide alone achieved at least 5% dTIR improvement at treatment end.

    In plain wordsIn insulin-naive Asian Pacific people with diabetes, 53.0% receiving lixisenatide alone improved time in glucose range by at least 5%.

    Peptide
    Lixisenatide
    Outcome
    Not applicableAt least 5% dTIR improvement with lixisenatide alone
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Patients with dTIR improvement of 5% or higher at end of treatment
    53%
    Lixi alone, LixiLan-O-AP

    Source sentences

    Summary
    In LixiLan-O-AP, the proportions of patients achieving 70% or higher dTIR or 5% or higher dTIR improvement at EOT with iGlarLixi were 77.5% and 77.8%, respectively, higher than with iGlar (61.1% and 75.3%) or Lixi (47.0% and 53.0%).
    2 context sentences
    Summary · context
    LixiLan-O-AP was performed in insulin-naive T2D patients (n = 878) randomized to iGlarLixi, glargine 100 units/mL (iGlar) or lixisenatide (Lixi).
    Summary · context
    LixiLan-L-CN was performed in insulin-treated T2D patients (n = 426) randomized to iGlarLixi or iGlar.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT03798080

Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin

Sanofin = 42619 Feb 2019 to 1 Dec 2020

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 19 Jul 2022
CompletedPhase 3NCT03798054

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)

Sanofin = 87815 Feb 2019 to 1 Mar 2021

Type 2 Diabetes Mellitus

Trial pageClinicalTrials.govUpdated 19 Jul 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.